Potential Benefits of Selenium Supplementation in Reducing Insulin Resistance in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis.
Potential Benefits of Selenium Supplementation in Reducing Insulin Resistance in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis.
复制标题
补硒降低心脏代谢性疾病患者胰岛素抵抗的潜在益处：一项系统评价和荟萃分析。
DOI：
10.3390/nu14224933
复制
发表时间：
2022-11-21
期刊：
影响因子：
5.9
通讯作者：
Wang A
中科院分区：
文献类型：
--
作者：
Ouyang J;Cai Y;Song Y;Gao Z;Bai R;Wang A
背景：硒是一种微量元素，据报道可以有效调节葡萄糖和脂质代谢。然而，来自不同临床试验的补充硒治疗心脏代谢疾病（cmd）的证据相互矛盾。目的：本荟萃分析旨在确定补充硒对慢性阻塞性肺病患者胰岛素抵抗、葡萄糖稳态和脂质谱的影响。方法：从5个电子数据库中筛选补充硒治疗慢性阻塞性肺病的随机对照试验（rct）。胰岛素水平、胰岛素抵抗稳态模型评估（HOMA-IR）、空腹血糖（FPG）和糖化血红蛋白A1C （HbA1c）被定义为主要结局指标，脂质谱被认为是次要结局指标。结果：meta分析纳入了10项研究，涉及526名受试者。结果表明，硒补充显著降低血清胰岛素水平（标准化男性差异[SMD]: - 0.53, 95%可信区间[CI] [- 0.84, - 0.21], p = 0.001, I2 = 68%）和HOMA-IR (SMD: - 0.50, 95% CI [- 0.86, - 0.14], p = 0.006, I2 = 75%)，并增加高密度脂蛋白胆固醇（HDL-C）水平(SMD: 0.97；95% CI [0.26, 1.68], p = 0.007, I2 = 92%)，但对FPG、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）和极低密度脂蛋白胆固醇（VLDL-C）无显著影响。结论：目前的证据支持补充硒对降低胰岛素水平、HOMA-IR和增加HDL-C水平的有益作用。补充硒可能是降低慢性糖尿病患者胰岛素抵抗的有效策略。然而，需要更多高质量的临床研究来提高我们估计的确定性。
Background: Selenium is a trace element that has been reported to be effective in regulating glucose and lipid metabolism. However, there is conflicting evidence from different clinical trials of selenium supplementation in treating cardiometabolic diseases (CMDs). Objective: This meta-analysis aimed to identify the effects of selenium supplementation on insulin resistance, glucose homeostasis, and lipid profiles in patients with CMDs. Methods: Randomized controlled trials (RCTs) of selenium supplementation for treating CMDs were screened in five electronic databases. Insulin levels, homeostatic model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), and glycosylated hemoglobin A1C (HbA1c) were defined as the primary outcome markers, and lipid profiles were considered the secondary outcome markers. Results: Ten studies involving 526 participants were included in the meta-analysis. The results suggested that selenium supplementation significantly reduced serum insulin levels (standardized men difference [SMD]: −0.53; 95% confidence interval [CI] [−0.84, −0.21], p = 0.001, I2 = 68%) and HOMA-IR (SMD: −0.50, 95% CI [−0.86, −0.14], p = 0.006, I2 = 75%) and increased high-density lipoprotein cholesterol (HDL-C) levels (SMD: 0.97; 95% CI [0.26, 1.68], p = 0.007, I2 = 92%), but had no significant effect on FPG, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C). Conclusion: Current evidence supports the beneficial effects of selenium supplementation on reducing insulin levels, HOMA-IR, and increasing HDL-C levels. Selenium supplementation may be an effective strategy for reducing insulin resistance in patients with CMDs. However, more high-quality clinical studies are needed to improve the certainty of our estimates.
登录
查看更多内容
影响因子：
3.9
作者：
Alizadeh, Mohammad;Safaeiyan, Abdolrasoul;Gargari, Bahram Pourghassem
通讯作者：
Gargari, Bahram Pourghassem
影响因子：
0.6
作者：
通讯作者：
--
影响因子：
7.7
作者：
GREENFIELD, MS;DOBERNE, L;REAVEN, G
通讯作者：
REAVEN, G
影响因子：
3.7
作者：
Abdulmalek, Shaymaa A.;Balbaa, Mahmoud
通讯作者：
Balbaa, Mahmoud
影响因子：
2.2
作者：
Farrokhian, A.;Bahmani, F.;Asemi, Z.
通讯作者：
Asemi, Z.